Steglatro (ertugliflozin) is a small molecule pharmaceutical. Ertugliflozin was first approved as Steglatro on 2017-12-19. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1. Steglujan's patent is valid until 2030-07-13 (FDA).
|Indication||type 2 diabetes mellitus|
|Drug Class||Phlorozin derivatives, phenolic glycosides|